Help us: Donate
Follow us on:
×

Tag: Clinical Trials

George Church Interview
Professor of Genetics at Harvard Medical School, a veteran geroscientist, and a serial entrepreneur, George Church hardly needs an introduction. While we are always happy to discuss the present and future of geroscience with him, this interview focuses on the two gene therapy papers that he recently co-authored, which drew a lot of attention due...
Longeveron
Longeveron has just announced the first data from its Phase 2b clinical trial that targets frailty with Lomecel-B, an MSC-based cell therapy. A longevity strategy built in More and more, biotech start-ups are applying longevity strategies to their therapeutic pipelines. Among them, Longeveron stands out as one of the few companies taking a cell-based approach....
Strawberries are a source of fisetin.
We take a look at the popular supplement fisetin and see how it stacks up as a potential anti-aging supplement. What is Fisetin? Fisetin is a plant polyphenol and part of the flavonoid group in the flavonol sub-category.  It is present in many trees and plants, including Eudicotyledons, Acacia greggii, Quebracho colorado, Rhus cotinus, and...
Unity biotechnology logo
Unity Biotechnology has recently announced the launch of its Phase 1 study of UBX1325 for patients with diabetic macular edema. The drug is designed to remove problematic senescent cells from the body which accumulate as we get older and are a reason we age. Why we Age: Cellular SenescenceAs your body ages, more of your...
Unity biotechnology logo
While we enjoy reporting positive news, we do occasionally have to report bad news, and today is one of those days. There has been some disappointing news from UNITY Biotechnology with the release of its Phase 2 senolytic trial of its candidate drug UBX0101. SOUTH SAN FRANCISCO, Calif., Aug. 17, 2020 (GLOBE NEWSWIRE) -- UNITY...
Today, we were pleased to hear that Samumed, a San Diego-based biotech company working on regenerative medicine, has just raised $438 million towards developing anti-aging therapies. SAN DIEGO – August 6, 2018 – Samumed, LLC, announced today that it has closed its A-6 Round of equity issuance with $438 million, bringing its total equity raised...